Ayodele Odutayo MD, DPhil , Bernard Zinman MD , Christoph Wanner MD , Isabella Zwiener PhD , Søren S. Lund MD , Stefan Hantel PhD , David Fitchett MD , Jacob A. Udell MD , EMPA-REG OUTCOME Trial Investigators
{"title":"在 EMPA-REG OUTCOME 中,动脉粥样硬化性心血管疾病诊断合格与否对心血管风险和安格列酮治疗效果的影响","authors":"Ayodele Odutayo MD, DPhil , Bernard Zinman MD , Christoph Wanner MD , Isabella Zwiener PhD , Søren S. Lund MD , Stefan Hantel PhD , David Fitchett MD , Jacob A. Udell MD , EMPA-REG OUTCOME Trial Investigators","doi":"10.1016/j.cjco.2024.01.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 inhibitor is unknown.</p></div><div><h3>Methods</h3><p>This study is a secondary analysis of the <strong>Empa</strong>gliflozin Cardiovascular <strong>Outcome</strong> Event Trial in Type 2 Diabetes Mellitus Patients–<strong>R</strong>emoving <strong>E</strong>xcess <strong>G</strong>lucose (EMPA-REG OUTCOME), which compared empagliflozin to placebo in adults with T2DM and atherosclerotic CV disease (ASCVD). Participants were categorized based on the time since their last qualifying ASCVD diagnosis (≤ 1 year vs > 1 year). Qualifying ASCVD diagnoses included ischemic or hemorrhagic stroke, myocardial infarction, coronary artery disease, and peripheral artery disease. The primary outcome was a composite of CV death, nonfatal myocardial infarction, or nonfatal stroke.</p></div><div><h3>Results</h3><p>A total of 6796 participants (n = 4547 empagliflozin, n = 2249 placebo) were included. Median time since the last qualifying ASCVD diagnosis was 3.8 years (quartile 1-quartile 3: 1.5-7.6), and most qualifying diagnoses occurred > 1 year before randomization (≤ 1 year, n = 1214; > 1 year, n = 5582). Empagliflozin reduced the incidence of the primary outcome irrespective of the time since the last qualifying ASCVD diagnosis (≤ 1 year: hazard ratio 0.82, 95% confidence interval: 0.57-1.16; vs > 1 year: hazard ratio 0.85, 95% confidence interval: 0.72-1.00; <em>P</em> for interaction = 0.84). Results were similar for the composite of CV death or hospitalization for heart failure.</p></div><div><h3>Conclusions</h3><p>Empagliflozin improved CV outcomes in participants with T2DM, irrespective of the time since the last qualifying ASCVD diagnosis at randomization. Prospective trials are necessary to investigate the use of sodium-glucose co-transporter 2 inhibitors at the time of an acute ASCVD event.</p></div><div><h3>Trial Registration</h3><p>EMPA-REG OUTCOME (<span>Clinicaltrials.gov</span><svg><path></path></svg> identifier: <span>NCT01131676</span><svg><path></path></svg>).</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 868-875"},"PeriodicalIF":2.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24000490/pdfft?md5=2e2314ae9ff76d3b5a18bafe9ae541a3&pid=1-s2.0-S2589790X24000490-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial\",\"authors\":\"Ayodele Odutayo MD, DPhil , Bernard Zinman MD , Christoph Wanner MD , Isabella Zwiener PhD , Søren S. Lund MD , Stefan Hantel PhD , David Fitchett MD , Jacob A. Udell MD , EMPA-REG OUTCOME Trial Investigators\",\"doi\":\"10.1016/j.cjco.2024.01.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 inhibitor is unknown.</p></div><div><h3>Methods</h3><p>This study is a secondary analysis of the <strong>Empa</strong>gliflozin Cardiovascular <strong>Outcome</strong> Event Trial in Type 2 Diabetes Mellitus Patients–<strong>R</strong>emoving <strong>E</strong>xcess <strong>G</strong>lucose (EMPA-REG OUTCOME), which compared empagliflozin to placebo in adults with T2DM and atherosclerotic CV disease (ASCVD). Participants were categorized based on the time since their last qualifying ASCVD diagnosis (≤ 1 year vs > 1 year). Qualifying ASCVD diagnoses included ischemic or hemorrhagic stroke, myocardial infarction, coronary artery disease, and peripheral artery disease. The primary outcome was a composite of CV death, nonfatal myocardial infarction, or nonfatal stroke.</p></div><div><h3>Results</h3><p>A total of 6796 participants (n = 4547 empagliflozin, n = 2249 placebo) were included. Median time since the last qualifying ASCVD diagnosis was 3.8 years (quartile 1-quartile 3: 1.5-7.6), and most qualifying diagnoses occurred > 1 year before randomization (≤ 1 year, n = 1214; > 1 year, n = 5582). Empagliflozin reduced the incidence of the primary outcome irrespective of the time since the last qualifying ASCVD diagnosis (≤ 1 year: hazard ratio 0.82, 95% confidence interval: 0.57-1.16; vs > 1 year: hazard ratio 0.85, 95% confidence interval: 0.72-1.00; <em>P</em> for interaction = 0.84). Results were similar for the composite of CV death or hospitalization for heart failure.</p></div><div><h3>Conclusions</h3><p>Empagliflozin improved CV outcomes in participants with T2DM, irrespective of the time since the last qualifying ASCVD diagnosis at randomization. Prospective trials are necessary to investigate the use of sodium-glucose co-transporter 2 inhibitors at the time of an acute ASCVD event.</p></div><div><h3>Trial Registration</h3><p>EMPA-REG OUTCOME (<span>Clinicaltrials.gov</span><svg><path></path></svg> identifier: <span>NCT01131676</span><svg><path></path></svg>).</p></div>\",\"PeriodicalId\":36924,\"journal\":{\"name\":\"CJC Open\",\"volume\":\"6 7\",\"pages\":\"Pages 868-875\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2589790X24000490/pdfft?md5=2e2314ae9ff76d3b5a18bafe9ae541a3&pid=1-s2.0-S2589790X24000490-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CJC Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589790X24000490\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X24000490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
Background
In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 inhibitor is unknown.
Methods
This study is a secondary analysis of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME), which compared empagliflozin to placebo in adults with T2DM and atherosclerotic CV disease (ASCVD). Participants were categorized based on the time since their last qualifying ASCVD diagnosis (≤ 1 year vs > 1 year). Qualifying ASCVD diagnoses included ischemic or hemorrhagic stroke, myocardial infarction, coronary artery disease, and peripheral artery disease. The primary outcome was a composite of CV death, nonfatal myocardial infarction, or nonfatal stroke.
Results
A total of 6796 participants (n = 4547 empagliflozin, n = 2249 placebo) were included. Median time since the last qualifying ASCVD diagnosis was 3.8 years (quartile 1-quartile 3: 1.5-7.6), and most qualifying diagnoses occurred > 1 year before randomization (≤ 1 year, n = 1214; > 1 year, n = 5582). Empagliflozin reduced the incidence of the primary outcome irrespective of the time since the last qualifying ASCVD diagnosis (≤ 1 year: hazard ratio 0.82, 95% confidence interval: 0.57-1.16; vs > 1 year: hazard ratio 0.85, 95% confidence interval: 0.72-1.00; P for interaction = 0.84). Results were similar for the composite of CV death or hospitalization for heart failure.
Conclusions
Empagliflozin improved CV outcomes in participants with T2DM, irrespective of the time since the last qualifying ASCVD diagnosis at randomization. Prospective trials are necessary to investigate the use of sodium-glucose co-transporter 2 inhibitors at the time of an acute ASCVD event.